Publications

Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia.

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with

Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.

Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.

Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.

[Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival].

Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection.